As the industry looks toward 2026, oral solid dosage forms remain firmly at the center of pharmaceutical and nutraceutical innovation — but the forces shaping the market are becoming more complex and interconnected.
Much like the winemakers who learned to harness pressure rather than fear it, OSD manufacturers are leveraging advances in manufacturing processes, formulation science, excipients and packaging technologies.
One element that is sometimes overlooked is data integrity from in vivo testing. Specifically, is data garnered from stressed species valid and/or reliable? Is it reproducible?
Advances in technologies, data, and development strategies are reshaping how oral solid dosage drugs are designed and manufactured, with a clear emphasis on lowering cost, shortening timelines, and improving quality and reliability across the life cycle.
X-ray powder diffraction provides a window into the crystalline structure, enabling developers to identify and quantify phases with precision.